Akeso Achieves Key Milestone with First Patient Enrolled in Phase III Trial of Ivonescimab for Pancreatic Cancer
[City, State] – July 24, 2025 – Akeso, a biopharmaceutical company dedicated to developing innovative treatments for serious diseases, today announced a significant milestone with the enrollment of the first patient in its pivotal Phase III clinical trial of ivonescimab. This groundbreaking study will evaluate the efficacy and safety of ivonescimab, a novel bispecific antibody, as a treatment for patients with pancreatic cancer.
Pancreatic cancer remains one of the most challenging and deadliest cancers, with a significant unmet medical need. The initiation of this Phase III trial represents a crucial step forward in the development of ivonescimab, offering renewed hope for patients battling this aggressive disease.
Ivonescimab is engineered to simultaneously target two key pathways involved in tumor growth and immune evasion: VEGF and Ang-2. By blocking both pathways, ivonescimab aims to disrupt tumor angiogenesis (the formation of new blood vessels that feed tumors) and modulate the tumor microenvironment to enhance the body’s own immune response against cancer cells. This dual mechanism of action holds significant promise for improving treatment outcomes in pancreatic cancer.
“The enrollment of the first patient in our Phase III trial is a testament to the dedication and hard work of our clinical research teams and the commitment of patients and investigators to advancing this important research,” said [Name and Title of Akeso Spokesperson, e.g., Dr. Jane Doe, Chief Medical Officer at Akeso]. “We are incredibly encouraged by the potential of ivonescimab to make a meaningful difference for patients with pancreatic cancer, and we eagerly anticipate the progress of this study.”
The Phase III trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the primary endpoint of progression-free survival (PFS) in patients with advanced or metastatic pancreatic cancer who have progressed on or after standard-of-care chemotherapy. Secondary endpoints will include overall survival (OS), objective response rate (ORR), and duration of response (DOR), among others.
Akeso is committed to rigorous scientific investigation and patient safety throughout the clinical development process. The company is collaborating with leading oncologists and research institutions globally to ensure the trial is conducted to the highest standards.
The advancement of ivonescimab into Phase III clinical trials underscores Akeso’s ongoing commitment to innovation in oncology and its mission to bring life-changing therapies to patients in need. The company looks forward to sharing future updates as the trial progresses.
About Akeso: Akeso is a biopharmaceutical company committed to the discovery, development, and commercialization of innovative biologic drugs for the treatment of cancer and autoimmune diseases. The company has a robust pipeline of novel bispecific antibodies and other biologics targeting key pathways in disease pathogenesis. Akeso is dedicated to advancing science and delivering life-changing therapies to patients worldwide.
Forward-Looking Statements: This press release contains forward-looking statements regarding the development of ivonescimab and Akeso’s future prospects. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
Please note that the date provided in the original request (2025-07-24) is in the future. This article is written as if the event has occurred on that date.
Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer’ at 2025-07-24 01:14. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.